[Lotus]

Hi Lotus,
Not been on here for a while due to a slight breakdown with mental health issues. 

I hope that you've addressed those and are getting the help you need. 

But I am really pleased to see you back on here posting. I cannot speak for others but I am sure they will be just as happy to see you back on here.

 

Thank you Ian. There's a few individuals not happy I'm back, they must be dealing with estrogen dominance i guess. I'm glad to see back too. 

As for your treatment with the scans of your breasts, perhaps she was jealous of the shape and perfection of your lovely boobs, let's face it your recent photos show them off to perfection. (ENVY)
Take care Ian was Liz
 

Lol, I think you're right Ian, that technician displayed some transphobia. 

I've added a new twist to my topical program with the addition of vitamin D3 applied to the breasts with progesterone, the Vit D3 i use comes in a gel capsule and suspended in organic olive oil. When applied (i poke a hole in the gel capsule and add a few drops to each breast) with progesterone cream it works well into the breasts, adding ethyl alcohol helps to diffuse the combination. The combination makes perfect sense because vitamin D3 promotes IGF-1 as does progesterone cream. Vitamin D3 and protects against breast cancer. As I've mentioned I had my IGF-1 tested which came back in normal range… I recommend getting your IGF-1 tested and monitored. 

Additionally, promoting too much IGF-1 lowers estradiol via somatostatin pathway. 

Continuing the research, there's a strategy in using vitamin D3 and calcium (and actual relatable science) together in the Lotus NBE program, along with MSM that's been thought out very carefully that I've already. Vitamin D3 actually increases IGF-1, and Progesterone applied to the breasts activates GH and IGF-1 receptors, getting all the benefits directly, and not lost via oral delivery via other means. Taking MSM also increases IGF-1 as does melatonin.


Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency
Pietro Ameri et al. Eur J Endocrinol. 2013
Abstract

Objectives: Previous studies suggested that vitamin D modulates circulating IGF1. We investigated this effect in adults and its clinical relevance in the management of GH deficiency (GHD).

Design and methods: IGF1 levels were prospectively measured before and after 12 weeks of treatment with oral vitamin D3 (5000 or 7000 IU/week) vs no intervention in 39 subjects 61.9±7.9 years old. The frequency of IGF1 values ≥50th age- and sex-specific percentile in relation to vitamin D status, as determined by the concentration of 25-hydroxyvitamin D (25(OH)D), was retrospectively assessed in 69 GHD patients (57.4±16.6 years) on stable hormone replacement and with 25(OH)D and IGF1 concurrently measured.

Results: Treatment with 5000 and 7000 IU vitamin D3/week significantly raised 25(OH)D by 12.7±8.4 and 13.1±6.5 ng/ml respectively (both P<0.001 vs baseline). In the 7000 IU group, IGF1 levels also significantly increased by 31.3±36.7 ng/ml (P=0.01). Neither 25(OH)D nor IGF1 significantly varied in controls. IGF1 was ≥50th percentile more frequently in GHD patients with 25(OH)D levels ≥15 than <15 ng/ml(65.9 vs 40.0%, P<0.05). Logistic regression with adjustment for recombinant human GH (rhGH) dose, vitamin D supplements, gender, use of thyroid hormones, corticosteroids or estrogen/testosterone, and season revealed a significant positive association between ≥15 ng/ml 25(OH)D and IGF 1 ≥50th percentile (OR 4.4, 95% CI 1.0-18.8, P<0.05). A significant negative correlation between 25(OH)D concentrations and rhGH dose was found after correcting for age and IGF1 (β -0.042, P<0.01), but not after further adjusting for sex, thyroid, adrenal or gonadal replacement, and season (β -0.037, P=0.06).

Conclusions: Vitamin D increases circulating IGF1 in adults. As a result, a better vitamin D status may ease the achievement of normal IGF1 values in GHD.

Vitamin D regulates IGF1 concentrations in the liver, the main source of circulating IGF1

On Inhibiting somatostatin is in breast growers' interest to inhibit its action. Meaning when somatostatin is released it inhibits prolactin, oral estradiol, adenylyl cyclase, growth hormone and TSH (thyroid releasing hormone)...which also inhibits TRH (Thyrotropin releasing hormone). And inhibiting TRH means no prolactin production. In other words prolactin stimulates the lobules of breasts. Vitamin D3 and MSM are very important for alveolar stimulation. 

When you inhibit adenylyl cyclase you inhibit ATP production, and the end result of that is inhibiting aromatase.

See, estrogen stimulates prolactin and growth hormone, so by somatostatin inhibiting their action it seems like an awful waste for breast growth. 
https://www.sciencedirect.com/topics/neu...matostatin

Antibody experiments (1) have clearly shown that basal GH levels are elevated when somatostatin is neutralized. 

Somatomedin C has also been implicated in the negative feedback regulation of GH, at least partially by stimulating release of somatostatin (5). 
https://link.springer.com/chapter/10.100...-7886-4_18

Most effective way to block somatostatin is in the stomach. Supplements for inhibiting somatostatin are listed in post #4192. Still working on adding other inhibiting agents to the list asap.

When you inhibit adenylyl cyclase you inhibit ATP production, and the end result of that is it inhibits aromatase. 

Somatostatin is used for treating Gigantism and Acromegaly, and other various conditions:
https://www.drugs.com/drug-class/somatos...alogs.html

Somatostatin agonists for treatment of acromegaly
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697610/